← All trials
NCT03620253
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2018
- Primary completion
- Apr 30, 2019
- Completion date
- Oct 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TorontoLead sponsor
- Government of OntarioCollaborator
- University of TorontoReponsible party - principal investigator
- University of TorontoOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.